Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas

doi:10.5306/wjco.v16.i6.105601

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=0

Jun 24, 2025 (publication date) through Jun 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Jun 24, 2025; 16(6): 105601
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.105601

Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas

Efstathios T Pavlidis, Ioannis N Galanis, Theodoros E Pavlidis

Efstathios T Pavlidis, Ioannis N Galanis, Theodoros E Pavlidis, The 2^nd Department of Propaedeutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece

Author contributions: Pavlidis TE designed research, contributed new analytic tools; Pavlidis TE and Galanis IN analyzed data, review and approved the paper; Pavlidis ET performed research, analyzed data, review and wrote the article.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Theodoros E Pavlidis, MD, PhD, Professor, The 2^nd Department of Propaedeutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr

Received: January 30, 2025
Revised: April 8, 2025
Accepted: May 13, 2025
Published online: June 24, 2025
Processing time: 141 Days and 14.1 Hours

Core Tip

Core Tip: Pancreatic ductal adenocarcinoma is an aggressive malignancy with a delayed diagnosis and poor prognosis. The newest diagnostic tools and proper management are crucial for determining survival. The current approach must be multidisciplinary and individualized. Surgical resection alone is not enough; it must be accompanied by other novel therapeutic modalities, such as chemotherapy, radiotherapy, targeted gene therapy, immunotherapy and vaccines.